Elderly with systemic arterial hypertension and diabetes mellitus type 2
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Should participate 64 elderly with hypertension and diabetes mellitus; aged between 60 and 79 years; of both genders.
Exclusion criteria
Exclusion criteria: Seniors in use of injectable medications and insulin estaminas; uncontrolled hypertension; smokers or former smokers with cessation of tobacco less than 20 years; neurological diseases; symptomatic musculoskeletal disorders, severe obesity; malnutrition; severe kidney disease; recent history of carcinoma; heart disease than high blood pressure; lung disease; changes in cognitive behavior; physically active high intensity;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome, the mean difference will be adopted quadriceps strength, determined by the 1 RM test (maximal repetition), held in leg extension to his knees. The sample size calculation will be the average of quadriceps muscle strength of at least 5 kg, suggesting 64 participants, divided into two groups, experimental and control. Adopting a 5% significance level and 80% test power. | — |
Secondary
| Measure | Time frame |
|---|---|
| Displacement and walking speed, measured by the 6-minute walk test, which indicate improved displacement values ??greater than 576 meters for men and 494 meters for women. Waist circumference measured by tape measure in centimeters (cm) to indicate improved values ??must be greater than or equal to 80 cm for females and 94 cm for males. Cardiovascular risk, measured by the Framingham score, which uses% chance for the occurrence of cardiovascular events, and a 2% reduction in score indicates improvement. Perceived quality of life, assessed using the Quality of Life SF-36 questionnaire, this questionnaire is divided into eight areas, each scored from 0-100. The increase of 10 points in each score indicates better quality of life. Hypoglycemic drugs consumption, described in the medical prescriptions daily intake (milligrams / day - mg / day), indicating an improvement in the reduction of 5 mg / day for sulfolirunéias dipepitidil peptidase inhibitors classes and 4, and reduction of 100 mg / day to biguanide class. | — |
Countries
Brazil
Contacts
Universidade Federal de São Paulo